Introduction
Growth hormone research relies on peptides that stimulate endogenous GH release through distinct hypothalamic-pituitary mechanisms. CJC-1295 No DAC, ipamorelin, and tesamorelin are three of the most widely studied GH secretagogues, each targeting different receptor systems and producing unique GH release profiles. Understanding their individual and combined characteristics is essential for researchers designing somatotropic axis studies.
All three peptides are available from Proxiva Labs: CJC-1295 No DAC, Ipamorelin, and Tesamorelin, each with independent purity verification.
CJC-1295 No DAC Overview
Mechanism and Profile
CJC-1295 No DAC (Modified GRF 1-29) is a synthetic GHRH analog with four amino acid substitutions providing DPP-IV enzyme resistance. It binds the GHRH receptor on pituitary somatotrophs, amplifying GH pulse amplitude without altering pulse frequency. Its ~30-minute half-life supports pulsatile, physiological GH release patterns (Teichman et al., 2006, J Clin Endocrinol Metab, 91(3):799-805, PMID: 16278264).
- Receptor: GHRH receptor
- Action: Amplifies GH pulse amplitude
- Selectivity: High (GHRH-specific)
- Half-life: ~30 minutes
Ipamorelin Overview
Mechanism and Profile
Ipamorelin is a pentapeptide GHRP that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. Unlike earlier GHRPs (GHRP-6, GHRP-2), ipamorelin stimulates GH release without elevating cortisol, prolactin, or ACTH at standard research concentrations. This selectivity makes it the cleanest GHRP available for controlled research (Raun et al., 1998, Eur J Endocrinol, 139(5):552-561, PMID: 9849822).
- Receptor: Ghrelin receptor (GHS-R1a)
- Action: Initiates GH pulse independently
- Selectivity: Exceptional (no cortisol/prolactin elevation)
- Half-life: ~2 hours
Tesamorelin Overview
Mechanism and Profile
Tesamorelin (formerly TH9507) is a stabilized GHRH analog consisting of the full 44-amino acid human GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification provides moderate DPP-IV resistance while maintaining the complete native receptor interaction. Tesamorelin has been extensively studied for visceral adiposity reduction and hepatic fat content, with its FDA-approved analog (Egrifta) targeting HIV-associated lipodystrophy (Falutz et al., 2007, JAMA, 298(14):1661-1673, PMID: 17925518).
- Receptor: GHRH receptor
- Action: Stimulates GH release, reduces visceral fat
- Selectivity: High (GHRH-specific)
- Half-life: ~26-38 minutes
- Unique feature: FDA-approved analog with body composition data
Three-Way Comparison
| Parameter | CJC-1295 No DAC | Ipamorelin | Tesamorelin |
|---|---|---|---|
| Drug Class | GHRH analog (modified) | GHRP (ghrelin mimetic) | GHRH analog (stabilized) |
| Receptor Target | GHRH-R | GHS-R1a (ghrelin-R) | GHRH-R |
| GH Release Mechanism | Amplifies existing pulse | Initiates new pulse | Amplifies existing pulse |
| Amino Acids | 29 (4 substitutions) | 5 | 44 (N-terminal modification) |
| Cortisol Effect | Minimal | None | Minimal |
| Prolactin Effect | None | None | None |
| Appetite Effect | None | Minimal | None |
| Visceral Fat Data | Limited | Limited | Extensive (FDA trials) |
| Bone Density Data | Limited | Positive preclinical | Limited |
| FDA History | Investigational | Investigational | FDA-approved analog (Egrifta) |
| Stacking Partner | Pairs with GHRPs | Pairs with GHRH analogs | Pairs with GHRPs |
Research Applications
The CJC-1295 + Ipamorelin Stack
The most studied combination in GH peptide research pairs CJC-1295 No DAC with ipamorelin, exploiting dual-receptor synergy. CJC-1295 amplifies GH pulse amplitude through the GHRH receptor while ipamorelin initiates GH pulses through the ghrelin receptor. Co-administration produces GH release exceeding the sum of each peptide alone. This combination also partially overcomes somatostatin inhibitory tone, enabling more robust GH elevation during natural trough periods.
Tesamorelin for Body Composition Research
Tesamorelin’s FDA-approved clinical dataset provides the most robust evidence linking GHRH analog administration to body composition outcomes. Studies demonstrated significant reductions in visceral adipose tissue (VAT) and trunk fat, with improvements in triglyceride levels. For researchers studying the GH axis’s role in fat distribution, tesamorelin provides the most clinically validated tool.
Comparative Receptor Studies
Using all three peptides in comparative protocols allows researchers to isolate receptor-specific contributions to GH release. CJC-1295 and tesamorelin both target the GHRH receptor but with different structural features, enabling structure-activity studies. Comparing either GHRH analog against ipamorelin reveals the distinct contributions of GHRH versus ghrelin receptor pathways to total GH output.
Practical Selection Guide
- For maximum pulsatile GH release: CJC-1295 No DAC + Ipamorelin combination
- For visceral fat and body composition studies: Tesamorelin (strongest clinical evidence)
- For clean, selective GH stimulation (no confounders): Ipamorelin alone
- For GHRH receptor pharmacology: CJC-1295 No DAC or Tesamorelin
- For ghrelin receptor pharmacology: Ipamorelin
Browse our complete research peptide catalog and visit our research guides for detailed protocol information.
Conclusion
CJC-1295 No DAC, ipamorelin, and tesamorelin provide researchers with three complementary tools for investigating the somatotropic axis. CJC-1295 offers DPP-IV-resistant GHRH receptor activation with superior pharmacokinetics. Ipamorelin provides the most selective ghrelin receptor agonism available, free of cortisol and prolactin confounders. Tesamorelin brings the deepest clinical evidence base, particularly for visceral adiposity and body composition endpoints. Together—especially CJC-1295 + ipamorelin in combination—they represent the gold standard in GH peptide research.
Shop all three at Proxiva Labs: CJC-1295 No DAC, Ipamorelin, and Tesamorelin. Every product includes third-party purity verification.
This article is for informational purposes only. All compounds mentioned are strictly for research use. Consult applicable regulations before purchasing research compounds.
All products are sold strictly for research purposes only. Not for human consumption.